Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | BAZ2B | Q9UIF8 | 8/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541660 | 0.91 | LMNA (0.78) | LMNASMN1; SMN2PABPC1ATMALDH1A1 | |
| SCHEMBL2486774 | 0.91 | LMNA (0.67) | LMNASMN1; SMN2PABPC1ATMALDH1A1 | |
| SCHEMBL12050177 | 0.86 | LMNA (0.60) | LMNASMN1; SMN2PABPC1ATMALDH1A1 | |
| SCHEMBL12127702 | 0.85 | LMNA (0.69) | LMNASMN1; SMN2PABPC1ATMALDH1A1 | |
| SCHEMBL602333 | 0.84 | LMNA (0.67) | LMNASMN1; SMN2PABPC1ATMALDH1A1 | |
| SCHEMBL940424 | 0.82 | LMNA (0.74) | LMNASMN1; SMN2PABPC1ATMALDH1A1 | |
| SCHEMBL407460 | 0.81 | LMNA (1.00) | LMNASMN1; SMN2PABPC1ATMALDH1A1 | |
| SCHEMBL941608 | 0.80 | LMNA (0.54) | LMNASMN1; SMN2PABPC1ATMALDH1A1 | |
| SCHEMBL61901 | 0.79 | LMNA (0.60) | LMNASMN1; SMN2PABPC1ATMALDH1A1 | |
| SCHEMBL10777655 | 0.79 | SMN1; SMN2 (0.79) | LMNASMN1; SMN2PABPC1ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076348-B2 | Acylguanidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-12-13 | — | — | US | disclosed |
| EP-1923387-B1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-2119704-A1 | ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-1923387-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | HTR5A, GRM5, HTR1E | LMNA 4558/4885SMN1; SMN2 4012/4885PABPC1 3278/4885 |
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | HTR2B, HTR7, HTR3B | LMNA 3388/4885SMN1; SMN2 1815/4885PABPC1 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.